Drug intelligence / Profile preview

PF-06940434

Development stage: Unknown
Lead developer: Pfizer
Modality: Small Molecules
Administration: Intravenous

Overview

PF-06940434 is an investigational intravenously administered drug developed by Pfizer. It acts as a selective antagonist of integrin alpha-V/beta-8 (αvβ8), also known as CD51, and is being studied primarily for its potential antineoplastic activity in advanced or metastatic solid tumors. By blocking integrin αvβ8, PF-06940434 inhibits the release of active transforming growth factor beta 1 and 3 (TGFβ1 & TGFβ3) into the tumor microenvironment, which may reduce tumor progression by modulating TGF-beta signaling pathways involved in immune suppression and tumor growth.

Other names: alpha v beta 8 inhibitoralpha V beta 8 antagonist PF-06940434integrin alpha V beta 8 inhibitorintegrin αvβ8 inhibitor

Targets

αVβ8 (Integrin alpha V beta 8)

Beyond the preview

Go deeper on PF-06940434.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF-06940434.

Explore the full profile